Helen Mackay

13.1k total citations · 4 hit papers
185 papers, 7.1k citations indexed

About

Helen Mackay is a scholar working on Reproductive Medicine, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Helen Mackay has authored 185 papers receiving a total of 7.1k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Reproductive Medicine, 60 papers in Oncology and 49 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Helen Mackay's work include Ovarian cancer diagnosis and treatment (68 papers), Endometrial and Cervical Cancer Treatments (45 papers) and Cancer Genomics and Diagnostics (25 papers). Helen Mackay is often cited by papers focused on Ovarian cancer diagnosis and treatment (68 papers), Endometrial and Cervical Cancer Treatments (45 papers) and Cancer Genomics and Diagnostics (25 papers). Helen Mackay collaborates with scholars based in Canada, United States and United Kingdom. Helen Mackay's co-authors include Amit M. Oza, Christopher Twelves, David G. Huntsman, Hal W. Hirte, Katia Tonkin, Kenneth D. Swenerton, Ana Oaknin, C. Blake Gilks, Euan Macpherson and James Carmichael and has published in prestigious journals such as Journal of Clinical Oncology, Nature reviews. Cancer and PLoS ONE.

In The Last Decade

Helen Mackay

173 papers receiving 7.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

2011 850 citations Helen Mackay, Hal W. Hirte et al. profile →
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial

2014 426 citations Amit M. Oza, Helen Mackay et al. profile →
Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative

2015 341 citations Ellen Stelloo, Tjalling Bosse et al. Modern Pathology profile →
Endometrial cancer

2021 340 citations Vicky Makker, Helen Mackay et al. profile →

Peers

Countries citing papers authored by Helen Mackay

Since Specialization

Citations

This map shows the geographic impact of Helen Mackay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Helen Mackay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Helen Mackay more than expected).

Fields of papers citing papers by Helen Mackay

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Helen Mackay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Helen Mackay. The network helps show where Helen Mackay may publish in the future.

Co-authorship network of co-authors of Helen Mackay

This figure shows the co-authorship network connecting the top 25 collaborators of Helen Mackay. A scholar is included among the top collaborators of Helen Mackay based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Helen Mackay. Helen Mackay is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	737P Characterization of tumor response with lenvatinib plus pembrolizumab (LEN + Pembro) in the ENGOT-en9/LEAP-001 study 2024 ·Annals of Oncology ·Anna Dańska-Bidzińska, (unknown), Vanda Salutari, Ali̇ Ayhan, Ignacio A. Romero, Tally Levy, (unknown), J.F. Baurain, Paweł Mach, (unknown), Helen Mackay, (unknown), (unknown), Brian M. Slomovitz, David S. Miller, Jodi A. McKenzie, Lan Yao, Vivek Khemka, Angélica Nogueira‐Rodrigues, Christian Marth	1
2	PARP inhibitors in non-ovarian gynecologic cancers 2024 ·Therapeutic Advances in Medical Oncology ·(unknown), Rania Chehade, Helen Mackay	2
3	Real-world outcomes associated with use of front-line bevacizumab in ovarian cancer 2023 ·Journal of Cancer Policy ·Josée-Lyne Ethier, Weidong Kong, Helen Mackay, Jacob McGee, Christopher M. Booth	2
4	748P Outcomes for patients (pts) with advanced endometrial cancer (aEC) who completed pembrolizumab (pembro) and continued lenvatinib (LEN) in the phase III Study 309/KEYNOTE-775 2023 ·Annals of Oncology ·Émeline Colomba, Domenica Lorusso, Helen Mackay, Richard G. Moore, Kan Yonemori, (unknown), (unknown), (unknown), Gianmaria Barresi, Jodi A. McKenzie, Vicky Makker	2
5	NRG‐GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer 2023 ·Cancer ·B.J. Rimel, Danielle Enserro, David Bender, (unknown), Annie Tan, (unknown), Mark E. Borowsky, John W. Moroney, Andrea Wahner Hendrickson, Floor Backes, Elizabeth M. Swisher, Matthew A. Powell, Helen Mackay	6
6	PR024/#394 Molecular profiling of P53 mutant endometrial cancer reveals distinct subgroups with opportunities for personalized therapeutic approaches 2023 ·Félix Blanc‐Durand, (unknown), Etienne Rouleau, Antoine Vasseur, Tjalling Bosse, Stephanie M. de Boer, Richard J. Edmondson, Melanie Powell, Emma J. Crosbie, Naveena Singh, Jessica N. McAlpine, Helen Mackay, Pamela M. Pollock, Linda Mileshkin, Clare L. Scott, (unknown), (unknown), Natalie Y.L. Ngoi, David S.P. Tan, Alexandra Léary	0
7	788P Molecular profiling of p53 mutant endometrial cancer reveals distinct subgroups with opportunities for personalized therapeutic approaches 2023 ·Annals of Oncology ·Félix Blanc‐Durand, Christopher M. Kramer, Etienne Rouleau, Damien Vasseur, Tjalling Bosse, Stephanie M. de Boer, Richard J. Edmondson, Melanie Powell, Emma J. Crosbie, Naveena Singh, Jessica N. McAlpine, Helen Mackay, Pamela M. Pollock, Linda Mileshkin, Clare L. Scott, Natalie Y.L. Ngoi, (unknown), (unknown), David S.P. Tan, Alexandra Léary	0
8	2022-RA-653-ESGO The impact of histology, prior therapy, and dMMR status on lenvatinib + pembrolizumab outcomes in patients with advanced endometrial cancer: A subgroup analysis of Study 309/KEYNOTE-775 2022 ·International Journal of Gynecological Cancer ·Domenica Lorusso, Vicky Makker, Antonio Casado, Bradley J. Monk, Helen Mackay, Alessandro D. Santin, David S. Miller, Richard G. Moore, Sally Baron‐Hay, Isabelle Ray‐Coquard, Ronnie Shapira‐Frommer, Kimio Ushijima, Kan Yonemori, Yong Man Kim, Eva María Guerra Alia, Ulus Ali Şanlı, (unknown), Jodi A. McKenzie, (unknown), Nicoletta Colombo	1
9	Quality of adverse event reporting in phase III randomized controlled trials of breast and colorectal cancer: A systematic review 2020 ·Cancer Medicine ·Adam S. Komorowski, Helen Mackay, Rossanna C. Pezo	9
10	HPV-independent Vulvar Squamous Cell Carcinoma is Associated With Significantly Worse Prognosis Compared With HPV-associated Tumors 2019 ·International Journal of Gynecological Pathology ·Ghassan Allo, Mei Ling Yap, Julie Cuartero, Michael Milosevic, Sarah E. Ferguson, Helen Mackay, Suzanne Kamel‐Reid, Ilan Weinreb, Danny Ghazarian, Melania Pintilie, Blaise Clarke	45
11	Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions 2019 ·Cells ·Marina Bagnoli, Tingyan Shi, Charlie Gourley, P Speiser, Alexander Reuß, Hans W. Nijman, Carien L. Creutzberg, Suzy Scholl, Anastassia Negrouk, Mark F. Brady, Kosei Hasegawa, Katsutoshi Oda, Iain A. McNeish, Elise C. Kohn, Amit M. Oza, Helen Mackay, David Millan, Katherine Bennett, Clare L. Scott, Delia Mezzanzanica	6
12	Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer 2016 ·Modern Pathology ·Inge C. van Gool, Ellen Stelloo, Remi A. Nout, Hans W. Nijman, Richard J. Edmondson, David N. Church, Helen Mackay, Alexandra Léary, Melanie Powell, Linda Mileshkin, Carien L. Creutzberg, Vincent T.H.B.M. Smit, Tjalling Bosse	66
13	Update on Intraperitoneal Chemotherapy for the Treatment of Epithelial Ovarian Cancer 2016 ·American Society of Clinical Oncology Educational Book ·Charlie Gourley, Joan L. Walker, Helen Mackay	9
14	HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology 2016 ·Archives of Pathology & Laboratory Medicine ·Angela N. Bartley, M. Kay Washington, Christina B. Ventura, Nofisat Ismaila, Carol Colasacco, Al B. Benson, Alfredo Carrato, Margaret L. Gulley, Dhanpat Jain, Sanjay Kakar, Helen Mackay, Catherine Streutker, Laura H. Tang, Megan L. Troxell, Jaffer A. Ajani	169
15	A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia 2015 ·Gynecologic Oncology ·Iván Díaz-Padilla, Michelle Wilson, Blaise Clarke, Hal W. Hirte, Stephen Welch, Helen Mackay, Jim Biagi, Michael Reedijk, Johanne I. Weberpals, Gini F. Fleming, Lisa Wang, Geoffrey Liu, Chen Zhou, (unknown), S. Percy Ivy, Amit M. Oza	62
16	PROGNOSTIC VALUE OF L1CAM EXPRESSION AND ITS ASSOCIATION WITH MUTANT P53 EXPRESSION IN HIGH-RISK ENDOMETRIAL CANCER PATIENTS: A TRANSPORTEC STUDY 2015 ·International Journal of Gynecological Cancer ·Inge C. van Gool, Ellen Stelloo, Remi A. Nout, Hans W. Nijman, Richard J. Edmondson, David N. Church, Helen Mackay, Alexandra Léary, (unknown), Linda Mileshkin, Carien L. Creutzberg, Vincent T.H.B.M. Smit, Tjalling Bosse	1
17	Vascular Endothelial Growth Factor Pathway Polymorphisms as Prognostic and Pharmacogenetic Factors in Cancer: A Systematic Review and Meta-analysis 2012 ·Clinical Cancer Research ·Lawson Eng, Abul Kalam Azad, Steven Habbous, Junxiong Pang, Wei Xu, Anke H. Maitland‐van der Zee, Sevtap Savas, Helen Mackay, Eitan Amir, Geoffrey Liu	45
18	Hedgehog pathway signaling in cervical carcinoma and outcome after chemoradiation 2011 ·Cancer ·Naz Chaudary, Melania Pintilie, David W. Hedley, Anthony Fyles, Michael Milosevic, Blaise Clarke, Rićhard P. Hill, Helen Mackay	50
19	Phase II/III Study of Intraperitoneal Chemotherapy after Neoadjuvant Chemotherapy for Ovarian Cancer: NCIC CTG OV.21 2011 ·Current Oncology ·Helen Mackay, (unknown), M. Heywood, (unknown), Elizabeth A. Eisenhauer, Amit M. Oza, Ralph M. Meyer	16
20	A phase II study of tomudex (T) in combination with epirubicin (E) and cisplatin (C) in patients with advanced oesophageal and gastric (OG) adenocarcinoma. 2000 ·Annals of Oncology ·Helen Mackay, Alyson W. MacInnes, (unknown), Nigel Raby, F. Lofts, M. Soukop, Andrew Harris, (unknown), J. Garcia‐Vargas, J. Evans	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact